Imarem

Imatinib, the active ingredient in Imarem, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It selectively blocks BCR‑ABL, c‑KIT and PDGFR enzymes, thereby inhibiting the growth of malignant cells in chronic myeloid leukemia and gastrointestinal stromal tumors, and is prescribed for adult patients requiring targeted cancer therapy.

GNH USA supplies Imarem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Imatinib is a tyrosine kinase inhibitor that targets specific oncogenic pathways in hematologic and solid tumor diseases. - Chronic myeloid leukemia (CML): achieves disease control by inhibiting the BCR‑ABL fusion protein, reducing leukemic cell proliferation. - Gastrointestinal stromal tumor (GIST): achieves tumor shrinkage by blocking c‑KIT and PDGFR signaling, limiting tumor growth. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by targeting BCR‑ABL driven leukemic blasts.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: swelling of hands, feet, or face. - Muscle cramps: involuntary tightening of muscles. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: dangerously low white blood cell count. - Thrombocytopenia: reduced platelet levels leading to bleeding risk. - Cardiac failure: reduced heart function or congestive symptoms. - Pulmonary hypertension: increased pressure in lung arteries. - Anaphylaxis: life‑threatening allergic reaction.

Before initiating Imarem, healthcare professionals should consider several safety measures. - Baseline blood counts: monitor complete blood count to detect cytopenias. - Liver function: assess hepatic enzymes and monitor for signs of hepatotoxicity. - Cardiac assessment: evaluate heart function in patients with pre‑existing cardiac disease. - Drug hypersensitivity: avoid use in individuals with known allergy to imatinib or its excipients. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Imatinib can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels and toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce imatinib exposure, compromising efficacy. - Antacids containing aluminum or magnesium: can decrease oral absorption of imatinib.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect, requiring INR monitoring. - Diuretics (e.g., furosemide): may exacerbate fluid retention. - Other tyrosine kinase inhibitors: concurrent use may increase risk of overlapping toxicities. - QT‑prolonging agents: combined use may raise risk of cardiac arrhythmias.